Targeting TPX2 to Enhance Metastasis Control and Radiosensitivity in Esophageal Squamous Cell Carcinoma Through...

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Esophageal squamous cell carcinoma (ESCC) presents significant challenges due to metastasis and variable radiosensitivity.
• The precise role of Targeting Protein for Xenopus Kinesin-like Protein 2 (TPX2) in these ESCC characteristics remains largely unelucidated.
• Investigating TPX2 is crucial for understanding ESCC progression and therapeutic resistance.

Purpose of the Study:

• To elucidate the functional significance of TPX2 in regulating metastasis and radiosensitivity within ESCC.
• To determine the molecular mechanisms underlying TPX2's influence on ESCC aggressiveness.
• To explore the potential of targeting TPX2 for improved ESCC treatment strategies.

Main Methods:

• Bioinformatic and experimental validation of TPX2 differential expression in ESCC tissues and cell lines.
• In vitro assays (wound healing, Transwell, colony formation, apoptosis) to assess migration, invasion, and radiosensitivity in TPX2-overexpressing ESCC cells.
• In vivo mouse models (xenograft, lung homing) to evaluate tumor growth, metastasis, and radiosensitivity.
• Examination of exosome-mediated TPX2 transfer and its effects on recipient cells.
• Analysis of the PI3K/AKT signaling pathway activation.

Main Results:

• TPX2 expression is significantly elevated in ESCC tissues and cell lines compared to normal controls.
• TPX2 overexpression markedly enhances ESCC cell migration, invasion, and radiosensitivity in vitro.
• In vivo studies demonstrate that TPX2 promotes metastasis and influences radiation response.
• Exosomes facilitate TPX2 transfer, conferring aggressive phenotypes to recipient ESCC cells.
• TPX2 activation of the PI3K/AKT pathway (indicated by a ~2.5-fold increase in p-AKT/AKT ratio) is a key mechanism driving enhanced metastasis and altered radiosensitivity.

Conclusions:

• TPX2 is identified as a critical regulator of malignant progression in ESCC.
• TPX2 promotes epithelial-mesenchymal transition, contributing to enhanced metastatic potential.
• Activation of the PI3K/AKT pathway by TPX2 is central to its role in ESCC aggressiveness and therapeutic response.
• Targeting TPX2 may offer a novel therapeutic strategy for managing ESCC metastasis and improving radiosensitivity.